series-c-plus
Stage
1
Investors
About
GlycoMimetics is a biotechnology company developing glycomimetic therapeutics that inhibit selectin-mediated cell adhesion to treat hematologic disorders and cancer, with clinical-stage candidates for acute myeloid leukemia and sickle cell disease.
Explore GlycoMimetics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.